Dassault Systèmes SE (DSY2.VI)
| Previous close | 35.09 |
| Open | 35.09 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 35.09 - 35.09 |
| 52-week range | 34.58 - 48.52 |
| Volume | |
| Avg. volume | 3 |
| Market cap | 47.221B |
| Beta (5Y monthly) | 0.58 |
| PE ratio (TTM) | 45.38 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.23 (0.64%) |
| Ex-dividend date | 27 May 2024 |
| 1y target est | N/A |
- Business Wire
Dassault Systèmes and Mistral AI Partner to Offer Trusted, AI-Powered Industry-Grade Solutions to Accelerate the Generative Economy
PARIS, July 01, 2024--Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) and Mistral AI today announced their partnership to bring the full power of frontier AI to industries in a trusted environment.
- Business Wire
Dassault Systèmes’ 3DEXPERIENCE Platform on the Cloud Selected by Mahindra & Mahindra as It Accelerates Its Digital Transformation
VELIZY-VILLACOUBLAY, France, June 20, 2024--Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) today announced that Mahindra & Mahindra, a leader in automotive, farm and services businesses in India, is advancing its digital transformation by selecting Dassault Systèmes’ 3DEXPERIENCE platform on the cloud to accelerate its end-to-end new product development process.
- Business Wire
Medidata Launches Clinical Data Studio, Leveraging AI to Modernize the Data Experience in Clinical Trials
NEW YORK, June 18, 2024--Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced the launch of Medidata Clinical Data Studio, a unified experience that unlocks the true power of clinical research data. This groundbreaking technology gives stakeholders greater control over the quality of data and the ability to deliver safer trials to patients faster.
